MYOSCREEN
LIVE

Serial Number

79382428

Owner

CYTOO

Attorney

Steven J. Solomon

Filing Date

May 26, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MYOSCREEN Trademark

Serial Number: 79382428 • Registration: 7691258

MYOSCREEN is a trademark filed by CYTOO on May 26, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

CYTOO (7 trademarks)

7 Parvis Louis Néhel,

Entity Type: 99

Trademark Details

Filing Date

May 26, 2023

Registration Date

February 18, 2025

Published for Opposition

December 31, 2024

Goods & Services

Pharmaceutical products, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; veterinary products, namely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; sanitary preparations for medical use; chemical and biological preparations for medical use, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases, and biological preparations for pharmaceutical use being biological preparations for use in cell cultures for medical purposes

Quality control and testing devices namely culture plates to test and conduct quality control in the field of biology, biotechnology and pharmacy; downloadable software for the collection, processing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instruments, namely computer hardware and downloadable software for data analysis, database management, data processing, in the field of life science research and the pharmaceutical industry market and diagnostics

Medical, biotechnological, and pharmaceutical research; research and development of chemical, biological and scientific products and materials in the biological, biotechnological, medical, diagnostic and pharmaceutical fields; scientific research, advisory and information services in the medical, biotechnological, pharmaceutical, diagnostic, technological and industrial fields; design and development of computers, software and computer platforms; technical testing namely technological testing in the scientific, biological, biotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testing, technical testing namely, technological testing in the scientific, biological, biotechnological and medical fields, and scientific research advisory services with respect to scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imaging, in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; diagnostic and industrial research in the biological, biotechnological and medical fields

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 19, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 31, 2025 FICS
FINAL DISPOSITION PROCESSED
Aug 31, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 18, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 19, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 31, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 31, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 18, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 18, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 31, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 31, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 22, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 22, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 22, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 22, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 22, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 23, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 16, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 25, 2024 RFCS
REFUSAL PROCESSED BY MPU
Mar 25, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 2, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 1, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 20, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 7, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 3, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 2, 2023 REPR